LIMN
Price
$1.07
Change
-$0.10 (-8.55%)
Updated
Nov 13 closing price
Capitalization
N/A
Intraday BUY SELL Signals
YDES
Price
$10.12
Change
+$1.28 (+14.48%)
Updated
Nov 13 closing price
Capitalization
715.79M
Intraday BUY SELL Signals
Interact to see
Advertisement

LIMN vs YDES

Header iconLIMN vs YDES Comparison
Open Charts LIMN vs YDESBanner chart's image
Liminatus Pharma
Price$1.07
Change-$0.10 (-8.55%)
Volume$209.43K
CapitalizationN/A
YD Bio
Price$10.12
Change+$1.28 (+14.48%)
Volume$73.13K
Capitalization715.79M
LIMN vs YDES Comparison Chart in %
LIMN
Daily Signal:
Gain/Loss:
YDES
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
LIMN vs. YDES commentary
Nov 14, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is LIMN is a Hold and YDES is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Nov 14, 2025
Stock price -- (LIMN: $1.17 vs. YDES: $8.84)
Brand notoriety: LIMN and YDES are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: LIMN: 15% vs. YDES: 200%
Market capitalization -- LIMN: $0 vs. YDES: $715.79M
LIMN [@Biotechnology] is valued at $0. YDES’s [@Biotechnology] market capitalization is $715.79M. The market cap for tickers in the [@Biotechnology] industry ranges from $110.25B to $0. The average market capitalization across the [@Biotechnology] industry is $2.1B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

LIMN’s FA Score shows that 1 FA rating(s) are green whileYDES’s FA Score has 0 green FA rating(s).

  • LIMN’s FA Score: 1 green, 4 red.
  • YDES’s FA Score: 0 green, 5 red.
According to our system of comparison, LIMN is a better buy in the long-term than YDES.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

LIMN’s TA Score shows that 3 TA indicator(s) are bullish while YDES’s TA Score has 5 bullish TA indicator(s).

  • LIMN’s TA Score: 3 bullish, 3 bearish.
  • YDES’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, both LIMN and YDES are a good buy in the short-term.

Price Growth

LIMN (@Biotechnology) experienced а -10.69% price change this week, while YDES (@Biotechnology) price change was -16.13% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.51%. For the same industry, the average monthly price growth was -3.12%, and the average quarterly price growth was +61.90%.

Industries' Descriptions

@Biotechnology (+1.51% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
YDES YTD gains are higher at: -21.422 vs. LIMN (-89.572).
LIMNYDESLIMN / YDES
CapitalizationN/A716M-
EBITDAN/AN/A-
Gain YTD-89.572-21.422418%
P/E RatioN/AN/A-
RevenueN/AN/A-
Total CashN/AN/A-
Total DebtN/AN/A-
TECHNICAL ANALYSIS
Technical Analysis
LIMNYDES
RSI
ODDS (%)
Bullish Trend 2 days ago
41%
Bullish Trend 2 days ago
33%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
35%
Bullish Trend 2 days ago
25%
Momentum
ODDS (%)
Bearish Trend 2 days ago
14%
Bearish Trend 2 days ago
14%
MACD
ODDS (%)
N/A
Bearish Trend 2 days ago
14%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
25%
Bearish Trend 2 days ago
15%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
31%
Bearish Trend 2 days ago
15%
Advances
ODDS (%)
Bullish Trend 17 days ago
43%
Bullish Trend about 1 month ago
17%
Declines
ODDS (%)
Bearish Trend 7 days ago
44%
Bearish Trend 4 days ago
11%
BollingerBands
ODDS (%)
N/A
Bullish Trend 2 days ago
38%
Aroon
ODDS (%)
Bearish Trend 2 days ago
40%
Bullish Trend 2 days ago
24%
View a ticker or compare two or three
Interact to see
Advertisement
LIMN
Daily Signal:
Gain/Loss:
YDES
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
LAAFX21.120.09
+0.43%
Lord Abbett Affiliated F
SHPCX14.550.04
+0.28%
Saratoga Health & Biotechnology C
RAZCX11.780.02
+0.17%
Russell Inv Multi-Asset Strat C
SCUIX32.230.02
+0.06%
Hartford Schroders US Small Cap Opps I
MUSBX38.410.01
+0.03%
MFS Blended Research Core Equity B

LIMN and

Correlation & Price change

A.I.dvisor tells us that LIMN and AIM have been poorly correlated (+29% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that LIMN and AIM's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To LIMN
1D Price
Change %
LIMN100%
+0.43%
AIM - LIMN
29%
Poorly correlated
+0.32%
SGMT - LIMN
27%
Poorly correlated
+3.76%
LYEL - LIMN
23%
Poorly correlated
+2.20%
BGMSP - LIMN
23%
Poorly correlated
+4.90%
ALT - LIMN
22%
Poorly correlated
-1.17%
More

YDES and

Correlation & Price change

A.I.dvisor tells us that YDES and OTLK have been poorly correlated (+21% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that YDES and OTLK's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To YDES
1D Price
Change %
YDES100%
N/A
OTLK - YDES
21%
Poorly correlated
+3.23%
LIMN - YDES
4%
Poorly correlated
+0.43%
OSRH - YDES
3%
Poorly correlated
+4.76%
HIND - YDES
3%
Poorly correlated
+0.19%
JBIO - YDES
3%
Poorly correlated
+2.04%
More